Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent NSCLC~* PDL1-positive status as determined by an immunohistochemistry assay performed by a central laboratory. A positive result in chemotherapy, chemoradiation of the tumor sample biopsy will satisfy the eligibility criterion~* Eastern Cooperative Oncology group Performance Status of 0 or 1~* Life expectancy greater than or equal to 12 weeks~* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors Version 1.1~* Adequate hematologic and end organ function~Exclusion Criteria:~* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exceptions are allowed. Hormone-replacement therapy or oral contraceptives, and tyrosine kinase inhibitors approved for treatment of NSCLC discontinued greater than 7 days prior to Cycle 1 Day 1~* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment~* Known central nervous system disease, including treated brain metastases in the following participants:~  1. who will not receive prior chemotherapy for advanced disease~ 2. who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (referred as 2L+ participants)~* Participants with a history of treated asymptomatic brain metastases are allowed in the 2L+ participants and previously treated for brain metastases.~* Leptomeningeal disease~* Uncontrolled tumor-related pain~* Uncontrolled hypercalcemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (MPDL3280): 1L Participants (Type: EXPERIMENTAL): Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
- Atezolizumab (MPDL3280): 2L+ Participants (Type: EXPERIMENTAL): Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
- Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants (Type: EXPERIMENTAL): Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).